Prelude Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Prelude Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,485	Closed	-$430K	–	2429
2021 Q3	$430K	Buy	+24,485	New	+$286K	0.01%	970
2017 Q3	–	Sell	-29,700	Closed	-$131K	–	1986
2017 Q2	$131K	Buy	29,700 +6,200	+26%	+$34.3K	0.01%	706
2017 Q1	$145K	Hold	23,500	–	–	0.01%	670
2016 Q4	$133K	Buy	23,500 +23,100	+5,775%	+$230K	0.02%	737
2016 Q3	$6K	Buy	400 +200	+100%	+$2.3K	﹤0.01%	1484
2016 Q2	$2K	Buy	+200	New	+$2.08K	﹤0.01%	1519

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Prelude Capital Management's TRIL Position: Q4 2021 in Review

Prelude Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 24,485 shares — an estimated $430K sold.

Prelude Capital Management first reported a position in TRIL in Q2 2016 and held it in 6 quarters. The position peaked at $430K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Prelude Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Prelude Capital Management sold 24,485 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $430K.
Prelude Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2016 and held it in 6 quarters.
Prelude Capital Management's Trillium Therapeutics Inc. position peaked at $430K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.